Activity of thrombin-activatable fibrinolysis inhibitor in the plasma of patients with abdominal aortic aneurysm

Blood Coagulation and Fibrinolysis

Volumn 25, Issue 3, 2014, Pages 226-231

  Dubis, Joanna ^a   Zuk, Natalia ^a   Grendziak, Ryszard ^a   Zapotoczny, Norbert ^a   Pfanhauser, Monika ^a   Witkiewicz, Wojciech ^a,b  

^a REGIONAL SPECIALIST HOSPITAL   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Abdominal aortic aneurysm; Fibrinolysis; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

CREATININE; D DIMER; FIBRIN DEGRADATION PRODUCT; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UREA; UROKINASE; UROKINASE RECEPTOR;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ARTICLE; CARDIAC PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ECHOGRAPHY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FIBRINOLYSIS; HUMAN; LEUKOCYTE COUNT; LIFESTYLE; MALE; PATHOGENESIS; PRIORITY JOURNAL; THICKNESS; THROMBOCYTE POOR PLASMA; UREA BLOOD LEVEL; BLOOD; HEMOSTASIS; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AORTIC ANEURYSM, ABDOMINAL; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 84897576737     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000028     Document Type: Article

References (47)

1. Lederle FA, Johnson GR, Wilson SE, Aneurysm Detection Management Veterans Affairs Cooperative Study. Abdominal aortic aneurysm in women. J Vasc Surg 2001; 34:122-126
2. Chichester Aneurysm Screening Group, Viborg Aneurysm Screening Study. Western Australian Abdominal Aortic Aneurysm Program; Multicentre Aneurysm Screening Study. A comparative study of the prevalence of abdominal aortic aneurysms in the United Kingdom, Denmark, and Australia. J Med Screen 2001; 8:46-50
3. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet 2005; 365:1577-1589
4. The UK, Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet 1998; 352:1649-1655
5. Middleton RK, Lloyd GM, Bown MJ, Cooper NJ, London NJ, Sayers RD. The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: A protein array study. Vasc Surg 2007; 45:574-580
6. Carrell TW, Burnand KG, Booth NA, Humphries J, Smith A. Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms. Vascular 2006; 14:9-16
7. Skagius E, Siegbahn A, Bergqvist D, Henriksson AE. Fibrinolysis in patients with an abdominal aortic aneurysm with special emphasis on rupture and shock. J Thromb Haemost 2008; 6:147-150
8. Lindholt JS, Jørgensen B, Shi GP, Henneberg EW. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2003; 25:546-551
9. Takagi H, Manabe H, Kawai N, Goto S, Umemoto T. Plasma fibrinogen and D-dimer concentrations are associated with the presence of abdominal aortic aneurysm: A systematic review and meta-Analysis. Eur J Vasc Endovasc Surg 2009; 38:273-277
10. Davies RS, Abdelhamid M, Wall ML, Vohra RK, Bradbury AW, Adam DJ. Coagulation, fibrinolysis, and platelet activation in patients undergoing open and endovascular repair of abdominal aortic aneurysm. J Vasc Surg 2011; 54:865-878
11. Odega° rd A, Lundbom J, Myhre HO, Hatlinghus S, Bergh K, Waage A, et al. The inflammatory response following treatment of abdominal aortic aneurysms: A comparison between open surgery and endovascular repair. Eur J Vasc Endovasc Surg 2000; 19:536-544
12. Abdelhamid MF, Davies RS, Adam DJ, Vohra RK, Bradbury AW. Changes in thrombin generation, fibrinolysis, platelet and endothelial cell activity, and inflammation following endovascular abdominal aortic aneurysm repair. J Vasc Surg 2012; 55:41-46
13. Vorp DA, Lee PC, Wang DH, Makaroun MS, Nemoto EM, Ogawa S, et al. Association of intraluminal thrombus in abdominal aortic aneurysm with local hypoxia and wall weakening. J Vasc Surg 2001; 34:291-299
14. Scott DJ, Prasad P, Philippou H, Rashid ST, Sohrabi S, Whalley D, et al. Clot architecture is altered in abdominal aortic aneurysms and correlates with aneurysm size. Arterioscler Thromb Vasc Biol 2011; 31:3004-3010
15. Kazi M, Thyberg J, Religa P, Roy J, Eriksson P, Hedin U, et al. Influence of intraluminal thrombus on structural and cellular composition of abdominal aortic aneurysm wall. Vasc Surg 2003; 38:1283-1292
16. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex. J Biol Chem 1996; 271:16603-16608
17. Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JC, Bouma BN. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101:4844-4846
18. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006; 26:2445-2453
19. Mutch NJ, Moore NR, Wang E, Booth NA. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003; 1:2000-2007
20. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. Biol Chem 1997; 272:14477-14482
21. Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85:5-11
22. Golledge J, Muller J, Shephard N, Clancy P, Smallwood L, Moran C, et al. Association between osteopontin and human abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 2007; 27:655-660
23. Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46:131-134
24. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278:51059-51067
25. Du XY, Zabel BA, Myles T, Allen SJ, Handel TM, Lee PP, et al. Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-Activable fibrinolysis inhibitor), and platelets. J Biol Chem 2009; 284:751-758
26. Uchida HA, Poduri A, Subramanian V, Cassis LA, Daugherty A. Urokinasetype plasminogen activator deficiency in bone marrow-derived cells augments rupture of angiotensin II-induced abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2011; 31:2845-2852
27. Rein CM, Cardenas JC, Church FC. The controversial role of the urokinase system in abdominal aortic aneurysm formation and rupture. Arterioscler Thromb Vasc Biol 2011; 31:2769-2771
28. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaître V, Tipping P, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17:439-444
29. Castellino FJ, Ploplis VA. Structure and function of the plasminogen/ plasmin system. Thromb Haemost 2005; 93:647-654
30. Persson M, Engström G, Bjö rkbacka H, Hedblad B. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study. Atherosclerosis 2012; 220:502-505
31. Schultz G, Tedesco MM, Sho E, Nishimura T, Sharif S, Du X, et al. Enhanced abdominal aortic aneurysm formation in thrombin-Activatable procarboxypeptidase B-deficient mice. Arterioscler Thromb Vasc Biol 2010; 30:1363-1370
32. Hobbs SD, Haggart P, Fegan C, Bradbury AW, Adam DJ. The role of tissue factor in patients undergoing open repair of ruptured and nonruptured abdominal aortic aneurysms. J Vasc Surg 2007; 46:682-686
33. Lindholt JS, Jørgensen B, Shi GP, Henneberg EW. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2003; 25:546-551
34. Gibney EJ, Bouchier-Hayes D. Coagulopathy and abdominal aortic aneurysm. Eur J Vasc Surg 1990; 4:557-562
35. Colucci M, Semeraro N. Thrombin activatable fibrinolysis inhibitor: At the nexus of fibrinolysis and inflammation. Thromb Res 2012; 129:314-319
36. Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116:113-121
37. Fontaine V, Jacob MP, Houard X, Rossignol P, Plissonnier D, Angles-Cano E, et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 2002; 161:1701-1710
38. Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA. Plasma thrombin-Activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2008; 20:912-916
39. Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, et al. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-I antigen levels in hyperthyroid patients. Endocr J 2007; 54:593-599
40. Gresele P, Binetti BM, Branca G, Clerici C, Asciutti S, Morelli A, et al. TAFI deficiency in liver cirrhosis: Relation with plasma fibrinolysis and survival. Thromb Res 2008; 121:763-768
41. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118:205-212
42. Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, et al. Activity and antigen levels of thrombin-Activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001; 104:1-6
43. Sayilir A, Beyazit Y, Yesil Y, Albayrak M, Ekiz F, Celik T, et al. Plasma thrombin-Activatable fibrinolysis inhibitor as an indicator of inflammation and disease severity in acute pancreatitis. Clin Res Hepatol Gastroenterol 2012; 36:498-504
44. de Bruijne EL, Gils A, Rijken DC, de Maat MP, Guimaräes AH, Poldermans D, et al. High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease. Thromb Res 2011; 127:254-258
45. Donmez A, Aksu K, Aydin H, Keser G, Cagirgan S, Doganavsargil E, et al. The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behçet disease and their association with thrombosis. Thromb Res 2010; 126:207-210
46. Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: A systematic review. Intensive Care Med 2012; 38:1418-1428
47. Lindqvist M, Wallinder J, Henriksson AE. Soluble urokinase plasminogen activator receptor in patients with abdominal aortic aneurysm. Thromb Res 2012; 130:1-3.